Anticoagulation not superior to placebo for calf DVT in low-risk patients, may increase bleeding risk
The randomized, double-blind, placebo-controlled trial examined a composite measure of extension of calf deep venous thrombosis (DVT) to proximal veins, contralateral proximal DVT, and symptomatic pulmonary embolism in a modified intention-to-treat population.
15 Nov 2016
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
12 Apr 2022
An additional 18 months of warfarin treatment in patients with first unprovoked PE improves outcomes versus placebo, although the improvement was not sustained after anticoagulant treatment was discontinued.
14 Jul 2015
Although the findings are most likely not a “game changer,” they may lead physicians to fine-tune their clinical practice.
9 Jun 2015
The benefits and risks of 8 different anticoagulation strategies for patients with venous thromboembolism (VTE), including heparin and new oral anticoagulants, were compared in a large new analysis.
23 Sep 2014
Anticoagulation for heart failure and afib associated with reductions in mortality, but maybe not readmissions
Starting anticoagulation for older patients with heart failure and atrial fibrillation at hospital discharge was associated with improved mortality at 1 and 3 years but was not associated with improved rates of all-cause cardiovascular readmission or stroke, a study found.
16 Sep 2014
NOACs linked to lower rates of diabetes complications than warfarin in patients with afib and diabetes
A retrospective study from Taiwan found that patients who received non-vitamin K antagonist oral anticoagulants (NOACs) developed fewer macrovascular and microvascular complications, had fewer glycemic emergencies, and were less likely to die than those who received warfarin.
15 Feb 2022
NSAIDs may increase bleeding, CV events when combined with antiplatelet or anticoagulant agents post-MI
Nonsteroidal anti-inflammatory drugs (NSAIDs) were associated with increased risk of bleeding and thrombotic events, even during short-term treatment, among patients receiving antithrombotic therapy after myocardial infarction (MI), a study found.
3 Mar 2015
Taking aspirin or an NSAID while on anticoagulant therapy significantly increases the risk of bleeding in patients who have had a venous thromboembolism (VTE), a recent study found.
22 Apr 2014
A new guideline for managing nonvalvular atrial fibrillation recommends using a more comprehensive risk calculator, diminishing aspirin's role, adding 3 new anticoagulants to treatment options, and increasing use of radiofrequency ablation.
1 Apr 2014